Bioengineers at The University of Texas at Dallas have created a novel gene-delivery system that shuttles a gene into a cell, but only for a temporary stay, providing a potential new gene-therapy strategy for treating disease.
The approach offers distinct advantages over other types of gene therapies under investigation, said Richard Taplin Moore MS’11, a doctoral student in bioengineering in the Erik Jonsson School of Engineering and Computer Science. He is lead author of a study describing the new technique in the Jan. 30 issue of the journal Nucleic Acids Research.
“In other gene therapy approaches, the therapeutic genetic messages being delivered can persist for a long time in the patient, potentially lasting for the patient’s entire lifetime,” Moore said. “This irreversibility is one reason gene therapies are so difficult to get approved.”
The UT Dallas study describes proof-of-concept experiments in which a gene carrying instructions for making a particular protein is ordered to self-destruct once the cell has “read” the instructions and made a certain quantity of the protein. In its experiments with isolated human kidney cells, the research team successfully delivered — and then destroyed — a test gene that makes a red fluorescent protein.
More research is needed to determine whether and how well the system might work in living organisms. But Moore said the ultimate goal is to refine the method to deliver genes that produce therapeutic proteins or drugs. The nature of the gene delivery system offers more control over how much protein the gene produces in cells or tissues. Because it does not alter the cell permanently, the method also sidesteps potential health problems that can occur if a gene is delivered to the wrong place in a cell’s genome.
“Our goal was to create a delivery system for therapeutic genes that would self-destruct, giving us more control over the delivered DNA by limiting the time it resides in cells,” Moore said.
Read more: Team Creates New Approach to Gene Therapy
The Latest on: Gene Therapy
via Google News
The Latest on: Gene Therapy
- Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Diseaseon June 25, 2019 at 5:15 pm
NEW YORK and CLEVELAND, June 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U.S. Food and Drug ... […]
- NextUp: The Local Company Pioneering Gene Therapy for Petson June 24, 2019 at 9:00 am
“NextUp” is a weekly NextHealth PHL feature that highlights the local leaders, organizations, and research shaping the Greater Philadelphia region’s life sciences ecosystem. Email [email protected] ... […]
- Adverum: Speculative Gene Therapy Play With In-House Capabilities Targeting The Validated And Attractive Ocular Spaceon June 24, 2019 at 7:30 am
Adverum is a clinical-stage gene therapy biotech targeting ocular and rare diseases. In addition to Adverum's clinical efforts, they are involved in their own novel vector discovery and in-house ... […]
- Translatable gene therapy for lung cancer using Crispr CAS9—an exploratory reviewon June 20, 2019 at 7:50 am
Gene therapy using CRISPR Cas9 technique is rapidly gaining popularity among the scientific community primarily because of its versatility, cost-effectiveness, and high efficacy. While the ... […]
- Q&A: Cancer Gene Therapy Researcher Bruce Levine on the Future of “Cellicon Valley”on June 20, 2019 at 7:13 am
Bruce Levine holds many titles. He serves as the Barbara and Edward Netter professor in cancer gene therapy and founding director of the Clinical Cell and Vaccine Production Facility (CVPF) in the ... […]
- Axovant and Yposkesi Sign Strategic Gene Therapy Development and Manufacturing Partnershipon June 20, 2019 at 5:00 am
Partnership secures access to reserved cGMP capacity and resources at Yposkesi for manufacturing to support the global development and commercialization of Axovant's gene therapy programs BASEL, ... […]
- Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Dealon June 19, 2019 at 9:03 am
Tip: Try a valid symbol or a specific company name for relevant results Give feedback on the new search experience Sign in Mail ... […]
- The Prickly Debate on Germline Gene Therapy, and Moving It Forwardon June 19, 2019 at 7:00 am
In 2016, a healthy baby boy came screaming into the world in a Mexican clinic. Harboring DNA from three parents, the baby had had his genes dramatically altered while still an embryo. Without the ... […]
- Gene Therapy will reach 84076.7 million USD by 2025 in United States marketon June 19, 2019 at 6:20 am
Jun 19, 2019 (MarketResearchNest via COMTEX) -- MarketResearchNest.com publishedThe "United States Gene Therapy Market Report 2018" report in its researchdatabase with report summary, table of content ... […]
- Boston research company bets on UT Southwestern researcher's gene therapyon June 18, 2019 at 3:36 pm
A biotech company founded on the research of a UT Southwestern Medical Center doctor is one step closer to a clinical trial after it was acquired by a Massachusetts company in a deal that could total ... […]
via Bing News